Sarah Krepp Sells 7,864 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 7,864 shares of Liquidia stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $562,354.64. Following the transaction, the insider owned 117,178 shares of the company’s stock, valued at $8,379,398.78. This trade represents a 6.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sarah Krepp also recently made the following trade(s):

• On Thursday, June 11th, Sarah Krepp sold 24,880 shares of Liquidia stock. The stock was sold at an average price of $70.28, for a total value of $1,748,566.40.
• On Monday, June 1st, Sarah Krepp sold 276 shares of Liquidia stock. The stock was sold at an average price of $60.87, for a total value of $16,800.12.

Liquidia Stock Up 1.6%

LQDA stock opened at $77.75 on Thursday. Liquidia Corporation has a twelve month low of $14.04 and a twelve month high of $82.96. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The stock’s 50 day moving average is $67.08 and its 200-day moving average is $47.81. The firm has a market capitalization of $6.91 billion, a PE ratio of 555.40 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. The business’s revenue was up 4187.1% on a year-over-year basis. Sell-side analysts expect that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Liquidia by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after purchasing an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after buying an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Liquidia by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after buying an additional 16,022 shares during the last quarter. Creative Planning grew its position in Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after buying an additional 7,765 shares during the period. Finally, Legal & General Group Plc grew its position in Liquidia by 13.4% during the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after buying an additional 11,111 shares during the period. Institutional investors own 64.54% of the company’s stock.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s YUTREPIA patent case appears to be turning more favorable, and the company is also being highlighted for expanding its patent position around the drug. That improves the outlook for protecting its pulmonary hypertension franchise and supports the bullish case for the stock. Liquidia (LQDA) Expands YUTREPIA As Patent Case Turns More Favorable
• Neutral Sentiment: Brokerage coverage remains constructive overall, with Liquidia receiving a consensus “Moderate Buy” rating from analysts. That supports the stock’s longer-term outlook, but it is not a new catalyst on its own. Liquidia Corporation (NASDAQ:LQDA) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Negative Sentiment: Several insiders, including the CEO, CFO, general counsel, CAO, and others, disclosed stock sales at about the same price level. The trades were made under pre-arranged 10b5-1 plans and tied to tax withholding from equity vesting, but the size and number of sales may still raise some investor caution. SEC filing – Roger Jeffs sale

Analysts Set New Price Targets

LQDA has been the subject of several recent analyst reports. Bank of America reiterated a “neutral” rating and issued a $79.00 target price (up from $64.00) on shares of Liquidia in a research note on Monday, June 29th. HC Wainwright raised their price target on shares of Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, June 5th. Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Liquidia in a report on Monday, May 11th. Needham & Company LLC upped their price objective on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).